Actively Recruiting
Primary Aldosteronism: a Study of Diagnostic Approach and Treatment Outcome in Western Norway
Led by Haukeland University Hospital · Updated on 2024-11-08
300
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
Sponsors
H
Haukeland University Hospital
Lead Sponsor
O
Oslo University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying patients with primary aldosteronism (PA) in Western and Mid-parts of Norway to understand the characteristics of these patients, the effects of PA on the heart before and after treatment, and long-term outcomes after treatment. The study includes a national registration of PA patients diagnosed or subtyped at Oslo University Hospital starting from 2022. This observational study aims to provide detailed information about PA and its treatment outcomes over time. Patients diagnosed with PA at Haukeland University Hospital since June 2013 are invited to join the study. Participants have baseline visits for clinical data registration and collection of blood and urine samples. A subgroup undergoes echocardiography before and one year after specific medical or surgical treatment for PA. Another subgroup participates in a cardiac MRI study using various imaging techniques including stress testing with adenosine, compared with healthy, age- and sex-matched controls. From 2025, PA patients diagnosed or subtyped at Oslo University Hospital will also be included. Participants attend regular follow-up visits after beginning treatment to monitor changes. The study measures long-term clinical and biochemical outcomes over five years, as well as heart function and structure using echocardiography and cardiac MRI over three years. Quality of life is also assessed. Healthy controls participate in the cardiac MRI substudy for comparison. The total participation time varies depending on the patient's subgroup and assessments.
CONDITIONS
Brief Title
Primary Aldosteronism in Western Norway
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Verified diagnosis or strong suspicion of primary aldosteronism
- Age 18-85
You will not qualify if you...
- Active cancer disease at time of inclusion
- Asthma or chronic obstructive pulmonary disease for cardiac MRI subgroup
- Use of dipyridamole for cardiac MRI subgroup
- Claustrophobia for cardiac MRI subgroup
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline visit
Participants undergo baseline clinical assessments and sample collections. Echocardiography is performed in a subgroup before treatment starts. A subgroup also undergoes cardiac MRI including stress testing with adenosine.
1 baseline visit (in-person)
Duration - Up to 5 years
Participants are followed up regularly after starting medical or surgical treatment, with clinical and biochemical assessments and repeated echocardiography or cardiac MRI in subgroups to assess treatment outcomes.
Regular follow-up visits over 5 years
Trial Site Locations
Total: 2 locations
1
Haukeland University Hospital
Bergen, Norway, 5021
Actively Recruiting
2
Oslo University Hospital
Oslo, Norway, 0424
Not Yet Recruiting
Research Team
M
Marianne A Grytaas, MD PhD
K
Kristian Løvås, Prof., MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here